Last reviewed · How we verify
0.25% bupivacaine with 1:200,000 epinephrine — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
0.25% bupivacaine with 1:200,000 epinephrine (0.25% bupivacaine with 1:200,000 epinephrine) — Jessyka Lighthall.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 0.25% bupivacaine with 1:200,000 epinephrine TARGET | 0.25% bupivacaine with 1:200,000 epinephrine | Jessyka Lighthall | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 0.25% bupivacaine with 1:200,000 epinephrine CI watch — RSS
- 0.25% bupivacaine with 1:200,000 epinephrine CI watch — Atom
- 0.25% bupivacaine with 1:200,000 epinephrine CI watch — JSON
- 0.25% bupivacaine with 1:200,000 epinephrine alone — RSS
Cite this brief
Drug Landscape (2026). 0.25% bupivacaine with 1:200,000 epinephrine — Competitive Intelligence Brief. https://druglandscape.com/ci/0-25-bupivacaine-with-1-200-000-epinephrine. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab